Humaid Al-Shamsi, Chairman at Nexomic, shared on LinkedIn:
“After treating thousands of patients with cancer – and losing far too many – I have come to believe we are approaching the limits of what the human mind alone can decode fast enough to meet the growing global cancer burden.
Cancer biology is now more complex than any single clinician, scientist, test, or dataset can fully interpret. That is why we founded Nexomic. At the heart of Nexomic is DeepOmic – our multi-omic AI tumor-agnostic foundation model, built to uncover the hidden biology behind treatment response, resistance, and relapse.
We are not trying to replace human expertise. We are expanding it. Our mission is to help answer the questions that matter most:
- Who will respond?
- Who will develop resistance?
- Who can safely be spared a treatment that will not work?
- Which therapy is most likely to change the course of a patient’s disease?
Every patient we have lost is a reminder that better decisions cannot wait. Not more data alone. No more guesswork , trial and error approach.
- Human expertise, amplified by AI.
- Deeper biology.
- Smarter and faster trials.
- Better decisions.
- Billions saved from saved and de-risk clinical trials.
This is the future. This is Nexomic!
Welcome to the future of smarter oncology decision and better patients outcome.”
